The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown

AIDS Reviews

Volumn 11, Issue 4, 2009, Pages 205-214

  Hlela, Carol ^a   Shepperd, Sasha ^a   Khumalo, Nonhlanhla P ^b   Taylor, Graham P ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

General population; HTLV 1; HTLV 1 infection; Prevalence

Indexed keywords

CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; HEALTH CARE SYSTEM; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INCIDENCE; NONHUMAN; PREVALENCE; REVIEW; SYSTEMATIC REVIEW;

AFRICA; ASIA; HAITI; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; PREVALENCE;

EID: 74249090847     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Verdonck K, Gonzàlez E, Van Dooren S, et al. Human T lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7:266-81.
2. HERN. Seroepidemiology of the human T-cell leukaemia/lymphoma viruses in Europe. The HTLV European Research Network. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:68-77.
3. Manns A, Hisada M, LaGranade L. Human T-lymphotropic virus type 1. Lancet. 1999;353:1951-8.
4. World Health Organisation (WHO). Acquired immunodeficiency syndrome. Proposed criteria for interpreting results from Western-blot assays for HIV-1, HIV-2 and HTLV-1/II. Weekly Epidemiological record. 1990;65:281-3.
5. Gessain A, Barin F, Vernant J, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985; 326:407-10.
6. Mochizuki M, Watanabe T, Yamaguchi K, et al. Uveitis associated with human T- lymphotropic virus type I: seroepidemiologic, clinical and virologic studies. J Infect Dis. 1992;166:943-4.
7. Eguchi K, Origuchi T, Takashima H, et al. Seroprevalence of anti-HTLV-1 antibody in rheumatoid arthritis. Arthritis Rheum. 1996;39:463-6.
8. LeGranade L, Schwartz R, Janniger C. Childhood dermatitis in the tropics: with special emphasis on infective dermatitis, a marker for infection with human T-cell leukemia virus-1. Cutis. 1996;58:115-18.
9. de The G, Bomford R. An HTLV-1 vaccine: why, how, for whom? AIDS Res Hum Retroviruses. 1993;9:381-6.
10. Murphy E, Figueroa J, Blattner W. Human T-lymphotropic virus type-1 (HTLV-1) seroprevalence in Jamaica. Am J Epidemiol. 1991;133:1114-24.
11. Taylor G. Seroepidemiology of the human T-cell leukaemia/lymphoma viruses in Europe. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13: 68-77.
12. Robert-Guroff M, Weiss S, Giron J, et al. Prevalence of antibodies to HTLV-1,-II and -III in intravenous drug abusers from an AIDS endemic region. JAMA. 1986;255:3133-7.
13. Wolfe N, Heneine W, Carr J, et al. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. Proc Natl Acad Sci USA. 2005;102:7994-9.
14. Calattini S, Chevalier S, Duprez R, et al. Discovery of a new human T-cell lymphotropic virus (HTLV-3) in Central Africa. Retrovirology. 2005;2:30.
15. Poiesz B, Ruscetti F, Gazdar A, et al. Detection and isolation of type C retrovirus from fresh and cultured lymphocytes of patients with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415-9.
16. What makes a good prevalence survey? In Evidence-based Dermatology. Radelescu M, et al. (Ed.) London: BMJ Books. 2003;1-9.
17. Grant W, Bia F, Chacko T, et al. Comparison of Enzyme-Linked Immunosorbent and indirect antibodies in sera from rural Haiti. Diagn Microbiol Infect Dis. 1992;15:121-4.
18. Roy M, Das M, Ishida T, et al. Absence of HTLV-1 infection in some Indian populations. Indian J Med Res. 1994;100:160-2.
19. Batsuuri J, Dashnyam B, Maidar J, et al. Absence of human T-lymphotropic virus type 1 in different populations in Mongolia. Scand J Infect Dis. 1993;25:398-9.
20. Yap S, Peh S, Chan L, et al. HTLV-1 antibody study in normal individuals and unselected hospital patients in Malaysia. Southeast Asian J Trop Med Public Health. 1992;23:26-9.
21. Kinoshita T, Imamura J, Nagai H, et al. Absence of HTLV-1 infection among seronegative subjects in an endemic area of Japan. Int J Cancer. 1993;54:16-19.
22. Morofuji-Hirata M, Kariyama W, Nakashima K, et al. Prevalence of antibody to HTLV type I in Okinawa, Japan, after an interval of 9 years. Am J Epidemiol. 1993;137:43-8.
23. Betherat E, Makuwa M, Renaut A, et al. HIV-1, HTLV-1 and HTLV-1I in a semiurban population in East Gabon. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:430-2.
24. LeHesran J, Delaporte E, Gaudebout C, et al. Demographic factors associated with HTLV-1 Infection in a Gabonese community. Int J Epidemiol. 1994;23:812-17.
25. Jeannel D, Kourouma K, Fretz C, et al. Regional differences in human retroviral infections HIV-1, HIV-2, and HTLV-1/II in Rural Guinea (West Africa). J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:315-18.
26. Sanders RC, Wai'in P, Alexander S, et al. The prevalence of antibodies to human T-lymphotropic virus type I in different population groups in Papua New Guinea. Arch Virol. 1993;130:327-34.
27. Takao S, Ishida T, Bhatia K, et al. Seroprevalence of human T-lymphotropic virus type 1 in Papua New Guinea and Irian Jaya measured using different Western blot criteria. J Clin Virol. 2000;16:129-33.
28. Vallinoto A, Pontes G, Muto N, et al. Identification of human T-cell lymphotropic virus infection in a semi-isolated Afro-Brazilian qulombo located in the Marajó Island (Pará, Brazil). Mem Inst Oswaldo Cruz. 2006;101:103-5.
29. Dourado I, Alcantara L, Barreto M, et al. HTLV-1 in the general population of Salvador, Brazil A city with African ethnic and sociodemographic characteristics. J Acquir Immune Defic Syndr. 2003;34:527-31.
30. Arango C, Maloney E, Rugeles M, et al. HTLV-1 and HTLV-1I coexist among the Embere and Inga Amerindians of Colombia. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:102-3.
31. Duenas-Barajas E, Bernal J, Vaught D, et al. Human retroviruses in Amerindians of Columbia: high prevalence of human T-cell lymphotropic virus type II infection among the Tunebo Indians. Am J Trop Med Hyg. 1993;49:657-63.
32. Inostroza J, Diaz P, Saunier C. Prevalence of antibodies to HTLV-1 in South American Indians (Maphuches) from Chile. Scand J Infect Dis. 1991;23:507-8.
33. Bouzas MB, Zapiola I, Quiruelas S, et al. HTLV type I and HTLV type II infection among Indians and Natives from Argentina. AIDS Res Hum Retroviruses. 1994;10:1567-71.
34. Tajima K. The 4th nationwide study of adult T-cell//leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer. 1990;45: 237-43.
35. Kaplan J, Osame M, Kubota H, et al. The risk of development of HTLV-1-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-1. J Acquir Immune Defic Syndr Hum Retrovirol. 1990; 3:1096-101. 35. Murphey EL, Hanchard B, Figueroa JP, et al. Modelling the risks of ATLL in persons infected with HTLV-1. Int J Cancer. 1989;43: 250-3.
36. Gessain A, Gout O. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-1). Ann Intern Med. 1992;117:933-46.
37. Mueller N. The Epidemiology of HTLV-1 infection. Cancer Causes Control. 1991;2:37-52.
38. Chandy M, Babu P, Saraswathy N, et al. HTLV-1 infection in patients with leukaemia in southern India. Lancet. 1991;338:380-1.
39. Andrade T, Dourado I, Galvào-Castro B, et al. Associations among the HTLV-1, HTLV-2 and HIV among injecting drug users in Salvador, Brazil. J Acquir Immune Defic Syndr. 1998;18:186-7.
40. Bittencourt A, Dourado I. Human T-cell lymphotropic virus type-1 infection among pregnant women in northeastern Brazil. J Acquir Immune Defic Syndr Hum Retrovirol. 2001;26:490-4.
41. Etenna S, Caron M, Besson G, et al. New insights into prevalence, genetic diversity and proviral load of human T-cell leukemia virus types -1 and 2 in pregnant women in Gabon in Equatorial Central Africa. J Clin Microbiol. 2008;46:3607-17.
42. Gastaldello R, Hall W, Gallego S, et al. Seroepidemiology of HTLV-1/II in Argentina: an overview. J Acquir Immune Defic Syndr Hum Retrovirol. 2004;35:301-8.
43. Trenchi A, Gastaldello R, Balangero M, et al. Retrospective study of the prevalence of human T-cell lymphotropic virus type 1/2, HIV and HBV in pregnant women in Argentina. J Med Virol. 2007;79:1974-8.
44. Vasquez P, Sanchez G, Volante C, et al. Human T-lymphotropic virus type-1: new risk for Chilean population. Blood. 1991;78:850-1.
45. Suarez M, Quero M, Ramírez A. Prevalence of HTLV-1 antibodies and possible risk factors in Chilean Prostitutes. Rev Med Chil. 1993;121: 614-7.
46. Zehender G, Ebranati E, Maddalena C, et al. Description of a "trans-Saharan" strain of human T-lymphotropic virus type 1 in West Africa. J Acquir Immune Defic Syndr Hum Retrovirol. 2008;47:269-73.
47. Mota-Miranda A, Araujo S, Dias J, et al. HTLV-1 infection in blood donors from western Brazilian Amazon region: Seroprevalence and molecular study of viral isolates. J Med Virol. 2008;80;1966-71.
48. Vallinoto A, Muto N. Serological and molecular evidence of HTLV-1 infection among Japanese immigrants living in the Amazon region of Brazil. Jpn J Infect Dis. 2004;57:156-9.
49. de-Thé G, Gessan A, Gazzolo L, et al. Comparative seroepidemiolgy of HTLV-1 and HTLV-1II in the French West Indies and some African countries. Cancer Res. 985;45(Suppl):4633-6s.
50. Maehama T. Human T cell leukemia virus-1 in pregnancy. Int J Gynaecol Obstet. 2004;87:247-8.
51. Tanggo Y, Gultom S, Simanjuntak T, et al. HTLV-1 in Indonesia, very low prevalence in the Jakarta: Antibodies in the healthy blood donors and various non hematological diseases. Intervirology. 2000;43:77-9.
52. Hunsmann G, Bayer H, Schneider J, et al. Antibodies to ATLV/HTLV-1 in Africa. Med Microbiol Immunol. 1984;173:167-70.